葛根素在呼吸系统疾病中的研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.04.013

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (4): 586-589.DOI: 10.3760/cma.j.issn.1007-1245.2024.04.013

葛根素在呼吸系统疾病中的研究进展

古路路吴福玲

滨州医学院附属医院儿科，滨州　256600

收稿日期:2023-09-19 出版日期:2024-02-01 发布日期:2024-03-07
通讯作者: 吴福玲，Email：Wufuling000@163.com
基金资助:
山东省自然科学基金（ZR2014HL001）；山东省医药卫生科技发展计划项目（2013WS0312）；滨州市软科学研究计划项目（2016BRK19）

Research progress of puerarin in respiratory diseases

Gu Lulu, Wu Fuling

Department of Pediatrics, Binzhou Medical University Hospital, Binzhou 256600, China

Received:2023-09-19 Online:2024-02-01 Published:2024-03-07
Contact: Wu Fuling, Email: Wufuling000@163.com
Supported by:
Natural Science Foundation of Shandong Province (ZR2014HL001); Medical Health Science and Technology Development Plan Project of Shandong Province (2013WS0312); Binzhou Soft Science Research Project (2016BRK19)

摘要/Abstract

摘要：

葛根素具有广泛的药理学特性，如抗炎、抗氧化、抗癌等作用。近年来的研究表明，葛根素在治疗呼吸系统疾病方面有许多优势。本文总结了葛根素在呼吸系统疾病中的最新进展，以期提供有应用前景的药物。

关键词:

葛根素, 呼吸系统疾病, 信号通路, 进展

Abstract:

Puerarin has a wide range of pharmacological properties, such as anti-inflammatory, antioxidant, and anticancer effects. Recent studies have shown that puerarin has many advantages in the treatment of respiratory diseases. This paper summarizes the latest progress of puerarin in respiratory diseases, in order to provide it with promising drugs.

Key words:

Puerarin, Respiratory diseases, Signal pathways, Progress

古路路吴福玲.

葛根素在呼吸系统疾病中的研究进展 [J]. 国际医药卫生导报, 2024, 30(4): 586-589.

Gu Lulu, Wu Fuling.

Research progress of puerarin in respiratory diseases [J]. International Medicine and Health Guidance News, 2024, 30(4): 586-589.

参考文献

[1] Zhang L. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine[J]. Drug Deliv, 2019, 26(1):860-869. DOI: 10.1080/10717544.2019.1660732.
[2] Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease[J]. J Clin Invest, 2008, 118(11):3546-3556. DOI: 10.1172/JCI36130.
[3] Wang J, Zhang T, Ma C, et al. Puerarin attenuates airway inflammation by regulation of eotaxin-3[J]. Immunol Lett, 2015, 163(2):173-178. DOI: 10.1016/j.imlet.2014.12.002.
[4] Pang W, Lan XM, Wang CB. Effect of puerarin on the release of interleukin-8 in co-culture of human bronchial epithelial cells and neutrophils[J]. Chin J Integr Med, 2012, 18(4):283-287. DOI: 10.1007/s11655-012-1054-6.
[5] Demehri S, Morimoto M, Holtzman MJ, et al. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma[J]. PLoS Biol, 2009, 7(5):e1000067. DOI: 10.1371/journal.pbio.1000067.
[6] 王文璐,何权,周林福.葛根素抑制支气管哮喘小鼠气道炎症和TSLP介导的Th2免疫作用的研究[J].南京医科大学学报(自然科学版),2022,42(10):1371-1375,1408. DOI:10.7655/NYDXBNS20221004.
[7] Yao RQ, Ren C, Xia ZF, et al. Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles[J]. Autophagy, 2021, 17(2):385-401. DOI: 10.1080/15548627.2020.1725377.
[8] Wen W, Yu G, Liu W, et al. Silencing FUNDC1 alleviates chronic obstructive pulmonary disease by inhibiting mitochondrial autophagy and bronchial epithelium cell apoptosis under hypoxic environment[J]. J Cell Biochem, 2019, 120(10):17602-17615. DOI: 10.1002/jcb.29028.
[9] Wang L, Jiang W, Wang J, et al. Puerarin inhibits FUNDC1-mediated mitochondrial autophagy and CSE-induced apoptosis of human bronchial epithelial cells by activating the PI3K/AKT/mTOR signaling pathway[J]. Aging (Albany NY), 2022, 14(3):1253-1264. DOI: 10.18632/aging.203317.
[10] 潘晓杰,范嘉铨,夏光琴.葛根素通过调节PINK1-parkin信号通路介导的线粒体自噬抑制慢性阻塞性肺疾病大鼠肺泡上皮细胞凋亡[J].中国病理生理杂志,2022,38(10):1833-1839. DOI:10.3969/j.issn.1000-4718.2022.10.013.
[11] Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2016, 138(1):16-27. DOI: 10.1016/j.jaci.2016. 05.011.
[12] Zhang P, Zhang Y, Wang L, et al. Reversal of NADPH oxidase-dependent early oxidative and inflammatory responses in chronic obstructive pulmonary disease by puerarin[J]. Oxid Med Cell Longev, 2022, 2022:5595781. DOI: 10.1155/2022/5595781.
[13] Pan B, Fang S, Zhang J, et al. Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor[J]. Comput Struct Biotechnol J, 2020, 18:3518-3527. DOI: 10.1016/j.csbj.2020.11.010.
[14] Qin X, Huang C, Wu K, et al. Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin[J]. J Cell Mol Med, 2021, 25(2):677-685. DOI: 10.1111/jcmm.16117.
[15] Zeng MS, Yu WD, Wang HX, et al. Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice[J]. Arch Virol, 2021, 166(9):2387-2397. DOI: 10.1007/s00705-021-05112-z.
[16] Wang HX, Zeng MS, Ye Y, et al. Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase[J]. Phytother Res, 2021, 35(1):324-336. DOI: 10.1002/ptr.6803.
[17] Zhang F, Wang Y, Liu P, et al. Puerarin exhibits antiinflammatory properties in gunpowder smog-induced acute lung injury in rats via regulation of the renin-angiotensin system and the NFκB signaling pathway[J]. Exp Ther Med, 2021, 22(2):809. DOI: 10.3892/etm.2021.10241.
[18] Zeng J, Zhao N, Yang J, et al. Puerarin induces molecular details of ferroptosis-associated anti-inflammatory on RAW264.7 macrophages[J]. Metabolites, 2022, 12(7):653. DOI: 10.3390/metabo12070653.
[19] Xu B, Wang H, Chen Z. Puerarin inhibits ferroptosis and inflammation of lung injury caused by sepsis in LPS induced lung epithelial cells[J]. Front Pediatr, 2021, 9:706327. DOI: 10.3389/fped.2021.706327.
[20] Deng HF, Wang S, Wang XL, et al. Puerarin protects against LPS-induced vascular endothelial cell hyperpermeability via preventing downregulation of endothelial cadherin[J]. Inflammation, 2019, 42(4):1504-1510. DOI: 10.1007/s10753-019-01014-0.
[21] Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic modulation of inflammasome pathways[J]. Immunol Rev, 2020, 297(1):123-138. DOI: 10.1111/imr.12908.
[22] Ning L, Wei W, Wenyang J, et al. Cytosolic DNA-STING-NLRP3 axis is involved in murine acute lung injury induced by lipopolysaccharide[J]. Clin Transl Med, 2020, 10(7):e228. DOI: 10.1002/ctm2.228.
[23] Ying Y, Mao Y, Yao M. NLRP3 inflammasome activation by microRNA-495 promoter methylation may contribute to the progression of acute lung injury[J]. Mol Ther Nucleic Acids, 2019, 18:801-814. DOI: 10.1016/j.omtn.2019. 08.028.
[24] Cai D, Zhao Y, Yu F. Puerarin ameliorates acute lung injury by modulating NLRP3 inflammasome-induced pyroptosis[J]. Cell Death Discov, 2022, 8(1):368. DOI: 10.1038/s41420-022-01137-8.
[25] Wang J, Sun N, Han W, et al. Long non-coding RNA CCAT1 sponges miR-490 to enhance cell proliferation and migration of non-small cell lung cancer[J]. Thorac Cancer, 2021, 12(3):364-371. DOI: 10.1111/1759-7714.13758.
[26] Zhao Y, Liu K, Li J, et al. Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy[J]. Drug Deliv, 2021, 28(1):1539-1547. DOI: 10.1080/10717544. 2021.1934187.
[27] 杨洁,郑凤龙,任喜尚.葛根素对人炎性因子肿瘤坏死因子-α诱导的小细胞肺癌细胞迁移和侵袭促进作用的影响及机制[J].中国老年学杂志,2020,40(3):616-620. DOI:10.3969/j.issn.1005-9202.2020.03.050.
[28] Lou Z, Lin W, Zhao H, et al. Alkaline phosphatase downregulation promotes lung adenocarcinoma metastasis via the c-Myc/RhoA axis[J]. Cancer Cell Int, 2021, 21(1):217. DOI: 10.1186/s12935-021-01919-7.
[29] Liu C, Li H, Jia J, et al. High metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) expression promotes proliferation, migration, and invasion of non-small cell lung cancer via ERK/mitogen-activated protein kinase (MAPK) signaling pathway[J]. Med Sci Monit, 2019, 25:5143-5149. DOI: 10.12659/MSM.913308.
[30] Lang J, Guo Z, Xing S, et al. Inhibitory role of puerarin on the A549 lung cancer cell line[J]. Transl Cancer Res, 2022, 11(11):4117-4125. DOI: 10.21037/tcr-22-2246.
[31] Hu Y, Li X, Lin L, et al. Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis[J]. Oncol Rep, 2018, 39(4):1731-1738. DOI: 10.3892/or.2018.6234.

葛根素在呼吸系统疾病中的研究进展

Research progress of puerarin in respiratory diseases

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	郑梅陆颖木大为. 铁死亡在阿尔茨海默病中的作用机制及研究进展 [J]. 国际医药卫生导报, 2024, 30(5): 705-709.
[2]	陈妙玲韩玉贞. PD-L1与肿瘤相关巨噬细胞在乳腺癌中的研究进展 [J]. 国际医药卫生导报, 2024, 30(5): 732-735.
[3]	孙春燕林晓青夏新建杨英亮. 2型糖尿病患者脑结构与糖化血红蛋白关系的影像学研究进展 [J]. 国际医药卫生导报, 2024, 30(5): 763-766.
[4]	潘广涛陈爱莹. 肠道免疫因素在炎症性肠病中的研究进展及治疗策略 [J]. 国际医药卫生导报, 2024, 30(4): 577-581.
[5]	陈秋宇刘享田叶莉萍田行瀚. ICU患者肺炎克雷伯菌血流感染的特点、新型诊断及治疗方案研究进展 [J]. 国际医药卫生导报, 2024, 30(4): 581-585.
[6]	于潇杰程立浩张浩张浩杰杨振林. 铁死亡与乳腺癌患者化疗耐药的关系研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 353-356.
[7]	刘茗刘帅张楠. 早期乳腺癌患者保乳术后免除放疗的研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 357-362.
[8]	刘淑娇张全意. 右美托咪定用于鞘内注射的研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 362-366.
[9]	范乐乐马靓翟怀香施童. 卒中后疲劳研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 381-385.
[10]	朱俊姚帅辉郭小磊. 右归丸辅助骨髓间充质干细胞对家兔骨质疏松性骨折愈合的影响及机制初探 [J]. 国际医药卫生导报, 2024, 30(3): 453-459.
[11]	孙鸿朔张治博李朋杜刚强姜建浩杨淑野. 儿童股骨干骨折治疗技术进展 [J]. 国际医药卫生导报, 2024, 30(2): 177-181.
[12]	张皓曹智洁李雪梅徐功铖李敏祁洪凯李增勇李伟. 运动损伤与功能性近红外光谱技术综述 [J]. 国际医药卫生导报, 2024, 30(2): 182-186.
[13]	卓雪峰刘建伟黄秉韬张敬敬张靖雨. 脏层胸膜浸润术前评估方法的研究进展 [J]. 国际医药卫生导报, 2024, 30(2): 187-191.
[14]	王燕张桂月陈翔. 替罗非班对进展性脑梗死患者血小板活性的影响及应用效果分析 [J]. 国际医药卫生导报, 2024, 30(2): 244-248.
[15]	商冠华田春梅. Nrf2信号通路作为虾青素治疗新靶点的研究进展 [J]. 国际医药卫生导报, 2024, 30(1): 20-24.